Gilead Sciences Halts Test of Bowel Disease Treatment
September 21 2016 - 07:05PM
Dow Jones News
By Ezequiel Minaya
Gilead Sciences Inc. (GILD) on Wednesday said it was halting
clinical studies of an experimental treatment for the bowel disease
ulcerative colitis following the recommendation of trial's
monitoring committee.
Gilead said that based on the company's review of the data,
"there is insufficient evidence of a treatment benefit" in the
group of patients receiving either one or two doses of the
treatment, known as GS-5745.
Ulcerative colitis is an inflammatory bowel disease linked to
long-lasting inflammation and ulcers in the digestive tract,
according to the Mayo Clinic.
The company said there were no safety concerns noted in the
monitoring committee's interim analysis. The trial was halted after
treating the first 150 patients of the planned 1,600-patient
trial.
Shares of Gilead slipped a nickel to $81.65 in after-hours
trading.
Gilead said ongoing trials involving GS-5745 and patients with
gastric cancer and Crohn's disease would continue as planned.
Write to Ezequiel Minaya at Ezequiel.Minaya@wsj.com
(END) Dow Jones Newswires
September 21, 2016 18:50 ET (22:50 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Feb 2024 to Mar 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2023 to Mar 2024